摘要血管内皮生长因子(VEGF)、血小板源性生长因子(PDGF)和补体在老年性黄斑变性(AMD)的发病过程中发挥着重要作用.以VEGF 165为靶分子获取的适配体哌加他尼钠已获美国食品与药品管理局批准用于渗出型AMD的治疗;而以PDGF-B、补体C5为靶分子获取的适配体E10030、ARC1905也已进入临床试验阶段,并均获得较好疗效.目前,针对AMD发病机制中多个作用靶点的联合治疗已成为AMD治疗的发展方向;多靶点拮抗的适配体目前已进入研发阶段,将可能成为AMD治疗的首选药物.

abstractsVascular endothelial growth factor (VEGF),platelet derived growth factor (PDGF) and complements play key roles in the pathogenesis of age-related macular degeneration (AMD).Pegaptanib,the first therapeutic aptamer against VEGF165,has been approved by the Food and Drug Administration (FDA) of US for the treatment of exudative AMD.Another two aptamers El0030 and ARC1905,each target PDGF-B and complement C5 respectively,are undergoing clinical trials.Recent trends to treat AMD are combined therapies targeting multiple key molecules in the pathogenesis of AMD;aptamers against multiple targets may become the preferred drug for AMD.